About the Company
Neuralstem Inc. is a biotechnology company headquartered in Rockville, Maryland that specializes in developing commercial-scale production of multiple types of central nervous system stem cells. In October 2019 Neuralstem announces that the company has changed its name to Seneca Biopharma, Inc. In April 2021 Seneca Biopharma merged with Leading BioSciences to form the combined company Palisade Bio, Inc.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $SNCA News
GT Biopharma Inc GTBP
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
SBFM Sunshine Biopharma, Inc.
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals. The company is ...
ABIO Stock Earnings: ARCA biopharma Reported Results for Q1 2024
ARCA biopharma just reported results for the first quarter of 2024.More From InvestorPlace The #1 AI Investment Might Be This ...
Sutro Biopharma Inc STRO
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Cue Biopharma Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
ARCA biopharma, Inc.
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for cardiovascular diseases. The firm focuses on ...
TBPH Theravance Biopharma, Inc.
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized ...
Q4 2023 Cue Biopharma Inc Earnings Call
Stephen Willey; Analyst; Stifel Financial Corp. Reni Benjamin; Analyst; JMP Securities LLC Operator Greetings, and welcome to the Cue Biopharma Investor Update Call. (Operator Instructions ...
Cue Biopharma Inc (CUE) Q4 2023 Earnings Call Transcript Highlights: Strategic Alliances and ...
Collaboration Revenue: Q4 2023: $1.8 million; Full Year 2023: $5.5 million. Research and Development Expenses: Q4 2023: $10.9 million; Full Year 2023: $40.8 million. General and Administrative ...
Immix Biopharma Suspends Stock Offering Pending New Prospectus
Immix Biopharma, Inc. (IMMX) has released an update. Immix Biopharma, Inc. has halted the offering of its common stock shares ...
Vor Biopharma, Inc.
Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to ...
Sunshine Biopharma Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...